An In-Depth Pharmacological and Clinical Review of OM-85 (Broncho-Vaxom): An Immunomodulatory Bacterial Lysate

Executive Summary

OM-85 is a complex biologic drug product, classified as an immunomodulatory bacterial lysate, with a long and extensive history of clinical use spanning over four decades. Marketed globally under the primary trade name Broncho-Vaxom®, it is approved in 64 countries for the prophylaxis of recurrent respiratory tract infections (RTIs) in both pediatric and adult populations. Its composition is a standardized, lyophilized extract derived from the alkaline lysis of 21 strains of eight bacterial species commonly implicated in respiratory disease. This unique composition provides a mixture of pathogen-associated molecular patterns (PAMPs) that engage the host immune system in a multifaceted manner.

The mechanism of action of OM-85 is distinct from both traditional vaccines and antibiotics. Upon oral administration, it interacts with the gut-associated lymphoid tissue (GALT), initiating a cascade of immune events via the gut-lung axis. This process involves the activation of both the innate and adaptive immune systems, leading to the maturation of dendritic cells, a balanced T-helper cell response (Th1/Th2/Treg), and a significant increase in protective antibodies, particularly secretory IgA (sIgA), at the respiratory mucosa. Recent research has further elucidated novel, host-directed antiviral properties, including the downregulation of cellular receptors like ACE2, which are critical for viral entry, positioning OM-85 as a potential broad-spectrum antiviral agent.

The clinical evidence supporting OM-85 is substantial, comprising numerous randomized controlled trials and a large body of real-world data. Multiple meta-analyses have consistently demonstrated its efficacy in reducing the frequency and duration of RTIs, as well as decreasing the associated use of antibiotics. This antibiotic-sparing effect represents a significant public health benefit in the era of rising antimicrobial resistance. The safety profile of OM-85 is exceptionally well-established and favorable; adverse events are uncommon, typically mild, transient, and comparable in frequency to placebo.

Despite its widespread global use and robust safety record, OM-85 faces a complex and evolving regulatory environment. It is at a critical juncture, defined by the tension between its legacy market approvals and the stringent evidentiary standards of major regulatory agencies. The European Medicines Agency (EMA) has recently restricted its indication to the prophylaxis of recurrent RTIs (excluding pneumonia) and has mandated the submission of new clinical data by 2026. In the United States, OM-85 remains an investigational product and is not approved for commercial use. However, the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application, enabling pivotal clinical trials to proceed, primarily focusing on the prevention of recurrent wheezing in young children—a significant unmet medical need and a potential precursor to asthma. The outcomes of these U.S.-based trials will be a determinative factor in the future global trajectory of OM-85, potentially solidifying its clinical value with high-quality, contemporary evidence or prompting a broader re-evaluation of its role in modern medicine.

Product Identification and Compositional Analysis

Nomenclature and Classification

The medication is identified by the generic name OM-85 and is assigned the DrugBank Accession Number DB16533.[1] It is a biotech product, reflecting its biological origin and complex nature. Its formal classification is multifaceted, categorized as a biologic, an immunologic factor, a complex mixture, and a bacterial/tissue extract.[1] This array of classifications highlights that OM-85 is not a single chemical entity but rather a composition of multiple biological molecules, a characteristic that presents distinct challenges for manufacturing, characterization, and regulatory assessment when compared to conventional small-molecule pharmaceuticals.

OM-85 is marketed globally under several trade names, with Broncho-Vaxom® being the most prominent and widely recognized.[3] Additional synonyms and brand names used in various markets include OM 85 BV, Broncho-Munal®, Ommunal®, Vaxoral®, and Paxoral®.[1]

Detailed Composition

OM-85 is a standardized, lyophilized (freeze-dried) extract produced through the alkaline lysis of 21 distinct strains of eight key bacterial species.[4] These species were selected because they are among the most common pathogens responsible for respiratory tract infections in humans. The consistent listing of these eight species across scientific literature underscores the standardized nature of the product's biological source material.[3]

The active components of OM-85 are a complex mixture of molecules derived from the bacterial cell walls. This includes a variety of immunologically active structures such as lipopolysaccharides (LPS) from Gram-negative bacteria and lipoteichoic acid from Gram-positive bacteria, as well as peptides and amino acids.[3] The product is specifically described as a "low-endotoxin" lysate, which indicates a controlled manufacturing process designed to mitigate the potentially toxic effects of high concentrations of LPS while preserving the essential immunomodulatory components of the bacterial extracts.[9]

The specific manufacturing process of "alkaline lysis" is a critical attribute that defines the final composition and biological activity of OM-85.[4] The method of bacterial lysis—whether chemical (alkaline) or mechanical—profoundly influences which bacterial components are extracted and their biochemical state. This, in turn, dictates the specific profile of Pathogen-Associated Molecular Patterns (PAMPs) present in the final product.[4] Comparative studies have suggested that mechanically produced lysates may induce a stronger pro-inflammatory response, whereas the alkaline lysis process used for OM-85 may yield a product with a more balanced,

modulatory character.[14] This distinction is fundamental to understanding the product's favorable safety profile and its unique mechanism of action. Consequently, clinical data and mechanistic understanding derived from OM-85 cannot be directly extrapolated to other bacterial lysate products prepared via different methods.

The eight bacterial species that form the basis of OM-85 are detailed in Table 1.

Table 1: Composition of OM-85 Bacterial Lysate

Bacterial Species	Gram Stain & Clinical Relevance
Haemophilus influenzae	Gram-negative. A common cause of respiratory infections, including sinusitis, bronchitis, and pneumonia.
Streptococcus pneumoniae (or Diplococcus pneumoniae)	Gram-positive. A leading cause of community-acquired pneumonia, otitis media, and meningitis.
Klebsiella pneumoniae	Gram-negative. Associated with pneumonia, particularly in hospital settings or in individuals with compromised immune systems.
Klebsiella ozaenae	Gram-negative. A subspecies of Klebsiella implicated in certain chronic respiratory conditions.
Staphylococcus aureus	Gram-positive. A versatile pathogen causing a range of infections, including sinusitis and pneumonia, often as a secondary infection.
Streptococcus pyogenes	Gram-positive. Primarily known for causing streptococcal pharyngitis ("strep throat") but can also lead to more severe respiratory infections.
Streptococcus viridans (or sanguinis)	Gram-positive. Part of the normal oral flora but can be opportunistic pathogens in the respiratory tract.
Moraxella catarrhalis (or Neisseria/Branhamella catarrhalis)	Gram-negative. A significant cause of otitis media in children and exacerbations of chronic obstructive pulmonary disease in adults.

Comprehensive Mechanism of Action

The therapeutic effects of OM-85 are derived from its ability to act as a potent immunomodulator, orchestrating a coordinated response from both the innate and adaptive immune systems. Its oral route of administration is central to its mechanism, leveraging the sophisticated immunological network of the gut-lung axis to confer protection at the primary site of respiratory infections.

Immunomodulation of the Innate Immune System via the Gut-Lung Axis

Upon oral administration, the lyophilized bacterial extracts in OM-85 are formulated to withstand the acidic environment of the stomach and transit to the small intestine.[4] Here, they interact with the gut-associated lymphoid tissue (GALT), a critical site for immune surveillance. The primary interface for this interaction is the Peyer's patches, specialized lymphoid follicles in the intestinal wall.[3]

The complex mixture of bacterial molecules within OM-85 serves as a rich source of PAMPs. These conserved molecular structures, such as LPS and lipoteichoic acid, are recognized by pattern recognition receptors (PRRs) expressed on the surface of immune cells.[4] Specialized M cells within the Peyer's patches actively transport these bacterial antigens across the intestinal epithelium, delivering them to underlying populations of antigen-presenting cells, most notably dendritic cells (DCs) and macrophages.[4] The engagement of PRRs, including Toll-like receptors 2 and 4 (TLR2 and TLR4), on these cells triggers the initiation of the innate immune response.[4]

This initial recognition event leads to several key downstream effects:

1. Dendritic Cell Maturation: The interaction with PAMPs induces the terminal maturation of DCs. This process transforms them from passive sentinels into potent activators of the adaptive immune system, a critical step in bridging the innate and adaptive responses.[3]
2. Activation of Innate Effector Cells: Other innate immune cells, such as macrophages and Natural Killer (NK) cells, are also activated, enhancing their phagocytic and cytotoxic capabilities.[4]
3. Cytokine Production: Activated innate cells begin to secrete a range of pro-inflammatory and antiviral cytokines. Key among these is interferon-beta (IFN-β), a Type I interferon with potent antiviral effects. Other important cytokines produced include interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-α), which help to orchestrate the broader immune response.[1]

This cascade of events, initiated in the gut, does not remain localized. The concept of the "gut-lung axis" is central to OM-85's efficacy. The activated immune cells, particularly the matured DCs, migrate from the GALT into the lymphatic system and eventually into systemic circulation. This process leads to the "homing" of these primed immune cells to distant mucosal sites, including the lymphoid tissue of the lungs, effectively strengthening the immune defenses at the site where respiratory pathogens are most likely to be encountered.[3]

Stimulation of the Adaptive Immune Response

Following their maturation in the GALT, dendritic cells migrate to the mesenteric lymph nodes, where they orchestrate the activation of the adaptive immune system.[4] By presenting the bacterial antigens they have processed, these DCs activate naive T lymphocytes, driving their differentiation into specific effector subsets.

The adaptive response stimulated by OM-85 is characterized by several key features:

1. T-Helper Cell Differentiation: OM-85 promotes a T-helper 1 (Th1) dominant response, which is crucial for mounting effective cellular immunity against intracellular bacteria and viruses. This includes the activation of cytotoxic CD8+ T cells capable of eliminating infected host cells.[4]
2. Regulatory T-Cell Activation: Concurrently, OM-85 also stimulates the expansion of T regulatory (Treg) cells. These cells play a vital role in immune homeostasis by suppressing excessive inflammation and preventing autoimmune reactions. This dual activation of both effector and regulatory T cells underscores the modulatory nature of OM-85, ensuring a robust but controlled immune response.[4] In pediatric populations, this effect is thought to be particularly important for restoring a healthy Th1/Th2 balance, which can be skewed towards allergy-promoting Th2 responses in early life.[4]
3. Humoral Immunity and Antibody Production: The activation of T-helper cells provides the necessary signals for B-cell activation, proliferation, and differentiation into antibody-producing plasma cells. This results in a significant increase in the production of immunoglobulins. The most critical of these is secretory IgA (sIgA), the primary antibody found in mucosal secretions. Elevated levels of sIgA in the saliva and airway lining provide a robust first line of defense, preventing pathogens from adhering to and invading the respiratory epithelium.[4] In addition to mucosal sIgA, increases in systemic serum levels of IgA and IgG are also observed.[16]

Novel Antiviral and Anti-inflammatory Pathways

Beyond its well-established role in priming the immune system against bacterial pathogens, recent research has uncovered additional, novel mechanisms of action for OM-85, particularly in the context of viral infections and local tissue defense.

A significant discovery, spurred by research during the COVID-19 pandemic, is the ability of OM-85 to act as a host-directed antiviral agent. Studies have demonstrated that OM-85 can downregulate the expression of host cell surface proteins that viruses use for entry. Specifically, it has been shown to reduce the expression of Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease, Serine 2 (TMPRSS2), the primary receptor and co-receptor for SARS-CoV-2, respectively.[9] This effect has been observed in both animal models and in primary human bronchial epithelial cells and is dependent on the innate immune signaling pathways mediated by MyD88 and TRIF.[9] By reducing the number of available receptors, OM-85 effectively "closes the door" to the virus, physically inhibiting its ability to infect cells. This mechanism represents a paradigm shift in understanding OM-85's function. It moves the drug beyond its role as a prophylactic for recurrent

bacterial infections and repositions it as a broad-spectrum, host-directed immunomodulator with significant antiviral capabilities. This mechanism is fundamentally different from that of vaccines, which target viral proteins. By targeting the host cell, this protective effect could be effective against multiple viral variants that utilize the same receptor for entry, a feature of immense strategic importance for pandemic preparedness.

This receptor modulation is complemented by OM-85's ability to boost general antiviral defenses. It is a potent inducer of Type I interferons, such as IFN-β, and key interferon-stimulated genes like RIG-I and ISG15.[5] This broad antiviral state has been shown to be effective against a range of viruses, including Respiratory Syncytial Virus (RSV) and human rhinovirus (hRV), in addition to coronaviruses.[14]

Furthermore, OM-85 has been shown to exert direct effects on the physical defense mechanisms of the respiratory mucosa. In studies using human sinonasal epithelial cells, OM-85 was found to stimulate the production of nitric oxide (NO) and significantly increase ciliary beat frequency.[10] This enhancement of mucociliary clearance, a critical mechanism for physically expelling trapped pathogens from the airways, is mediated through the activation of bitter taste receptor (T2R) signaling pathways, revealing another layer of its complex interaction with the respiratory epithelium.[10]

Clinical Development and Therapeutic Indications

The clinical development and application of OM-85 span several decades, establishing a primary indication in the prevention of recurrent respiratory infections while also exploring its potential in a range of inflammatory and allergic conditions.

Primary Indication: Prophylaxis of Recurrent Respiratory Tract Infections (RTIs)

The principal and most widely approved therapeutic indication for OM-85 is the prophylaxis of recurrent respiratory tract infections (RTIs) in both children and adults.[5] This indication is supported by a large volume of clinical data from randomized controlled trials, observational studies, and extensive post-marketing experience.

Numerous studies have consistently demonstrated that prophylactic treatment with OM-85 leads to a statistically significant reduction in the frequency of new RTI episodes.[5] This reduction in infection rate is accompanied by clinically meaningful secondary benefits, including a shorter duration of illness when infections do occur and, critically, a marked decrease in the need for antibiotic prescriptions.[5] The prophylactic effect has been observed to be most pronounced in patients who are at the highest risk of recurrence, such as young children in daycare settings or individuals with a history of frequent infections.[8]

In many countries, this indication is well-established in national guidelines and clinical practice. For instance, in Italy, OM-85 is officially registered for the prophylaxis of recurrent RTIs in adults and in children over one year of age.[5] A large retrospective cohort study conducted using the Italian Pedianet database confirmed its real-world effectiveness, showing a significant drop in both the mean number of RTI episodes and the frequency of antibiotic prescriptions in the 12-month period following initiation of OM-85 treatment compared to the 12 months prior.[5]

Recognizing a data gap in the elderly, a population highly vulnerable to severe outcomes from RTIs, a new Phase 4 clinical trial has been initiated (OM85OLDER, NCT06655272). This study is specifically designed to evaluate the efficacy and safety of OM-85 in preventing RTIs in individuals aged 75 years and older who reside in nursing homes, aiming to provide robust evidence for this important at-risk group.[25]

Investigational and Off-Label Applications

Building on its core immunomodulatory mechanism, OM-85 is being actively investigated for its therapeutic potential in a range of conditions characterized by immune dysregulation, particularly allergic and inflammatory diseases.

Asthma and Allergic Conditions

Given its ability to modulate the Th1/Th2 immune balance and promote regulatory T-cell responses, OM-85 is a logical candidate for intervention in Th2-dominant allergic diseases like asthma and atopic dermatitis (AD).[26]

• Allergic Asthma: Clinical development is exploring both oral and alternative routes of administration. A completed Phase 1 trial (NCT06486662) has assessed the safety and tolerability of a novel intranasal formulation of OM-85 (OM-85-IN) in healthy volunteers and patients with mild allergic asthma, suggesting a strategy to maximize local immunomodulatory effects in the airways.[26] Another Phase 1 trial is currently recruiting patients with atopic asthma.[27] Supporting this line of investigation, a retrospective real-world study in adults with moderate-to-severe allergic asthma found that adding OM-85 to standard-of-care therapy significantly reduced the frequency of RTI-related episodes, asthma exacerbations, and the need for oral corticosteroids and antibiotics.[23]
• Atopic Dermatitis (AD): The clinical strategy in AD is focused on early-life intervention to potentially alter the natural history of the "atopic march," where AD often precedes the development of asthma and allergic rhinitis. A completed Phase 3 trial (NCT03047954) investigated the use of OM-85 for the primary prevention of AD in children.[28] More recently, a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial (NCT05222516) evaluated the efficacy and safety of OM-85 as a treatment for established moderate AD in a very young population of children aged 3 to 24 months. This trial completed in July 2023.[29]

Pediatric Wheezing

Recurrent wheezing episodes in infancy and early childhood, often triggered by viral RTIs, are a major cause of morbidity and a strong predictor for the subsequent development of asthma.[9] OM-85 is being studied as a preventive therapy to interrupt this progression.

A key double-blind, randomized, placebo-controlled trial (NCT00733226) conducted in preschool children (aged 6 months to 6 years) with a history of recurrent wheezing demonstrated that treatment with OM-85 significantly prevented wheezing attacks over a 12-month follow-up period.[30] This area represents a major strategic focus for the manufacturer, OM Pharma, particularly in the United States. In a significant milestone, the U.S. FDA cleared an IND application in late 2022, allowing for a Phase 2b study of OM-85 for the prevention of recurrent wheezing episodes in children aged 6 months to 5 years.[31] A large, multicenter Phase 2 study (NCT05857930) is currently active and recruiting patients in the U.S. and other countries to further evaluate this indication.[33] Success in this area could establish OM-85 as a first-in-class therapy for preventing asthma development in high-risk children.

Chronic Obstructive Pulmonary Disease (COPD)

A substantial body of evidence also supports the use of OM-85 for the prevention of acute exacerbations in adult patients with chronic bronchitis and COPD. Multiple randomized clinical trials have shown that prophylactic treatment with OM-85 can reduce the number of acute exacerbations by 25% to 50% compared with placebo.[3] In addition to reducing exacerbation frequency, studies have reported secondary benefits such as a significant reduction in the duration of hospitalizations for respiratory causes and improvements in symptoms like dyspnea.[34] One trial noted that the beneficial effect on exacerbation rate was particularly pronounced in patients who were current or former smokers.[3]

Table 2: Summary of Pivotal Clinical Trials for Key Indications

NCT/EudraCT ID	Phase	Indication	Patient Population	Intervention & Dosage	Primary Outcome	Key Result/Status
NCT06655272	4	Prophylaxis of RTIs	≥75 years, nursing home residents with history of ≥2 RTIs	Bacterial Lysate vs. Placebo	Rate of RTIs over 12 months	Estimated Enrollment: 360. Not yet recruiting.
NCT05222516	2a	Treatment of Atopic Dermatitis	3 to 24 months with moderate AD	OM-85 (3.5 mg) daily vs. Placebo for 24 weeks	Change in EASI score	Completed July 2023. Results pending.
NCT05857930	2	Prevention of Wheezing Episodes	6 to 72 months with recurrent wheezing	OM-85 vs. Placebo daily for 6 months	Rate of wheezing/asthma-like episodes	Estimated Enrollment: 288. Recruiting.
NCT00733226	N/A	Prevention of Wheezing Attacks	6 months to 6 years with recurrent wheezing	OM-85 (3.5 mg) for 10 days/month for 3 months vs. Placebo	Number of wheezing attacks over 12 months	Completed. OM-85 prevented wheezing attacks.
PARI-IS Study	N/A	Prevention of COPD Exacerbations	Adults with COPD	OM-85 (7 mg) vs. Placebo	At least one acute exacerbation	Completed. No significant difference in primary outcome, but reduced hospitalization duration.
NCT03047954	3	Prevention of Atopic Dermatitis	6 months to 7 years	OM-85 (3.5 mg) daily vs. Placebo for 9 months	Evolution of disease	Completed. Results pending.

Synthesis of Clinical Efficacy from Systematic Reviews and Meta-Analyses

To obtain a consolidated view of the clinical efficacy of OM-85, numerous systematic reviews and meta-analyses (SRMs) have been conducted over the years. These analyses primarily focus on the drug's core indication: the prevention of recurrent RTIs in pediatric populations.[2]

The aggregated data from these reviews consistently point toward a beneficial effect. A comprehensive meta-analysis published in 2021, which included 14 randomized controlled trials with a total of 1859 pediatric subjects, provides a robust quantitative summary of the drug's efficacy. The pooled results demonstrated that, compared to placebo, treatment with OM-85 was significantly associated with [15]:

• A lower frequency of RTIs (Mean Difference of -1.16 episodes).
• A substantially shorter total duration of RTIs (MD of -19.51 days).
• A lower overall incidence of RTIs (Odds Ratio of 0.40, indicating a 60% reduction in odds).
• A significant reduction in antibiotic use (OR of 0.38).

These findings are broadly consistent with other major reviews, including a Cochrane review which concluded that immunostimulants, with OM-85 possessing the most robust evidence among them, could reduce the incidence of acute RTIs by approximately 36% to 40% on average when compared to placebo.[6]

However, a critical and recurring theme throughout the literature is the significant statistical and clinical heterogeneity among the individual trials included in these meta-analyses.[2] This variability, or "noise," complicates the interpretation of the pooled results. The source of this heterogeneity is multifactorial, stemming from differences in study design, patient populations (e.g., varying baseline risk of infection), geographical settings, primary endpoint definitions, and overall methodological quality of the original studies. A recent critical appraisal of the available SRMs, using the rigorous AMSTAR-2 tool for assessing methodological quality, found that only one of nine reviews on the topic could be rated as having "high confidence," with the majority rated as "critically low confidence".[2]

This context is essential for understanding the nuanced position of OM-85 in evidence-based medicine. While a consistent "signal" of efficacy clearly emerges from the totality of the data, the "noise" created by the heterogeneity and variable quality of the underlying trials prevents the formulation of definitive, high-grade recommendations according to the strictest standards of evidence. This evidentiary gap is a primary driver of the cautious stance adopted by major regulatory bodies like the EMA and explains the FDA's requirement for new, large-scale, and rigorously designed trials to provide an unambiguous confirmation of the drug's efficacy.

From a health economics perspective, analyses based on the observed efficacy have suggested that OM-85 is a cost-effective intervention. By reducing the incidence of RTIs, it consequently lowers direct healthcare costs associated with physician visits, emergency department consultations, and hospitalizations, as well as indirect costs such as parental absenteeism from work. The reduction in antibiotic consumption further contributes to its favorable economic profile.[14]

Safety, Tolerability, and Pharmacovigilance

The safety profile of OM-85 is a cornerstone of its clinical value proposition, having been well-characterized over more than four decades of widespread clinical use and numerous controlled trials.

Adverse Event Profile

Across the extensive body of clinical literature, OM-85 is consistently described as having a good to excellent safety and tolerability profile.[4] The overall incidence of adverse events reported in clinical trials is low, typically ranging from 3% to 4%, a rate that is not significantly different from that observed in placebo groups.[38] A formal meta-analysis of safety data confirmed this, finding no statistically significant difference in the rate of adverse events between patients receiving OM-85 and those receiving placebo (OR 1.02).[15]

When adverse events do occur, they are predominantly mild in severity and transient in nature. The most frequently reported side effects are related to the gastrointestinal system, including nausea, abdominal pain, vomiting, and diarrhea.[10] Dermatologic reactions, such as skin rashes and urticaria, have also been reported.[10] Respiratory symptoms, including coughing or dyspnea, are reported less commonly.[38] The favorable safety profile is a significant asset for a prophylactic medication, particularly one intended for long-term, intermittent use in pediatric populations.

Contraindications and Special Populations

The use of OM-85 is governed by a few specific contraindications and precautions:

• Hypersensitivity: The primary contraindication is a known hypersensitivity to the active substance or to any of the excipients contained in the formulation. Should an allergic reaction or signs of intolerance occur during treatment, the medication should be discontinued immediately.[41]
• Age Limitation: Due to a lack of sufficient clinical data in very young infants, the use of OM-85 is generally not recommended in children under the age of 6 months.[39]
• Pregnancy and Lactation: There is limited clinical data regarding the use of OM-85 in pregnant or lactating women. While animal studies have not indicated any direct or indirect toxicity, as a standard precautionary measure, its use during pregnancy and breastfeeding is preferably avoided.[41]
• Concomitant Medications: To date, no specific drug-drug interactions have been identified.[41] Of particular clinical importance, the co-administration of OM-85 with the seasonal influenza vaccine has been specifically studied and found to be safe. The combination does not interfere with the development of a protective immune response to the vaccine and is not associated with an increased incidence of adverse events.[44] This compatibility is a significant practical advantage, allowing for the concurrent use of both preventive strategies during the winter season.

Long-Term Safety

The safety of repeated courses of OM-85 has also been evaluated. A retrospective study that assessed the administration of OM-85 for two consecutive years in children with recurrent RTIs found that the safety profile remained favorable throughout the extended treatment period. Only a minority of patients experienced mild adverse events, confirming the drug's suitability for long-term prophylactic use in children who remain at high risk for infections over several years.[44]

Global Regulatory Landscape and Market Access

The regulatory status of OM-85 is complex and varies significantly across different global regions, reflecting a dynamic interplay between its long history of use and the evolving, more stringent evidentiary requirements of modern regulatory science.

European Medicines Agency (EMA) Status

In Europe, where OM-85 has been a mainstay for decades, its regulatory standing underwent a significant review by the EMA's Committee for Medicinal Products for Human Use (CHMP). In a decision issued in June 2019, the CHMP concluded that there was a lack of robust, contemporary data to support the efficacy of bacterial lysates for the treatment of existing respiratory infections or for the prevention of pneumonia.[22]

Consequently, the EMA restricted the approved indication for OM-85 and similar products across the European Union. The current harmonized indication is limited to the prophylaxis of recurrent respiratory tract infections, with the specific exclusion of pneumonia.[22] While the review acknowledged the favorable safety profile and found some evidence of effectiveness for this preventive use, the continued approval is conditional. The EMA has mandated that the marketing authorization holders must provide further data on safety and effectiveness from new, well-designed clinical studies, with a submission deadline of

2026.[22]

This decision places OM-85 at a critical regulatory inflection point in its most established market. Despite this restriction, the product remains authorized and available in numerous EU member states, including Austria, Belgium, the Czech Republic, Germany, Hungary, Italy, Poland, Portugal, Romania, Slovakia, and Slovenia.[22]

U.S. Food and Drug Administration (FDA) Status

In stark contrast to its status in Europe and other parts of the world, OM-85 is not currently approved or authorized for commercialization in the United States for any indication.[31] It is classified as an investigational product.

However, a formal regulatory pathway in the U.S. has recently been initiated. In a pivotal development in December 2022, the FDA cleared an Investigational New Drug (IND) application submitted by the manufacturer, OM Pharma.[31] This clearance allows the company to conduct clinical trials in the U.S. and represents the first major step toward potential marketing approval. The initial focus of this U.S. development program is on the prevention of recurrent wheezing in young children, a significant unmet medical need.[31]

Several clinical trials are now underway or actively recruiting in the U.S. These include a large, multicenter Phase 2 study sponsored by OM Pharma (NCT05857930) to assess the efficacy of OM-85 in reducing wheezing episodes in children, as well as a National Institutes of Health (NIH)-sponsored trial (NCT02148796) investigating its potential to prevent the development of wheezing and asthma-like symptoms in high-risk infants.[9] For patients with serious conditions who are unable to participate in these trials, access to the investigational drug may be available through Expanded Access Programs.[25] The success of these high-profile, rigorously designed trials will be the single most important determinant of OM-85's future in the U.S. market.

Rest of World (RoW) Approvals

OM-85 has an extensive global footprint, built over more than 40 years of marketing and clinical use. It is currently approved and marketed in 64 countries worldwide.[31] Its use is widespread throughout Europe, parts of South America, and Asia.[3] The specific regulatory status can vary by country; for example, it is available as a prescription drug in the Philippines [52], while in some other regions, it may be available over-the-counter.[51] This fragmented global regulatory landscape highlights the differing evidentiary standards and healthcare philosophies that exist across international jurisdictions.

The current situation places OM-85 at a global regulatory crossroads. Its future will be determined by the resolution of the tension between its legacy status, built on decades of real-world use in dozens of countries, and the high-evidence demands of the world's two most influential regulatory bodies, the FDA and the EMA. The data generated from the ongoing U.S. trials will be critical. A successful outcome could not only unlock the lucrative U.S. market but also provide the high-quality evidence required by the EMA to potentially reverse its 2019 indication restriction. Conversely, failure in these trials could have a negative ripple effect, emboldening the EMA to take further restrictive action and prompting other national regulators to re-evaluate their long-standing approvals.

Table 3: Global Regulatory Status Summary

Regulatory Body/Region	Approval Status	Approved Indication(s)	Key Considerations/Notes
European Medicines Agency (EMA)	Approved (Restricted)	Prophylaxis of recurrent respiratory tract infections (excluding pneumonia).	Use for treatment of active infections is not approved. Continued approval is conditional on submission of new clinical data by 2026.
U.S. Food and Drug Administration (FDA)	Investigational (Not Approved)	Not applicable.	IND application cleared in Dec 2022. Pivotal Phase 2/3 trials are ongoing, primarily for pediatric recurrent wheezing.
Rest of World (e.g., South America, Asia, non-EU Europe)	Approved	Primarily for the prophylaxis of recurrent RTIs in adults and children.	Marketed in 64 countries. Regulatory status (e.g., prescription vs. over-the-counter) and specific indications may vary by country.

Comparative Analysis and Strategic Outlook

The clinical and strategic positioning of OM-85 is best understood by comparing its mechanism and application to the primary alternative strategies for managing recurrent respiratory infections: prophylactic antibiotics and traditional vaccines.

Positioning Against Prophylactic Antibiotics

Recurrent RTIs are a major driver of antibiotic prescribing, particularly in pediatric populations, where RTIs can account for up to 75% of all antibiotic courses.[8] The long-term, low-dose use of prophylactic antibiotics has been a strategy to manage these recurrences, but it is a deeply problematic approach due to its direct contribution to the global crisis of antimicrobial resistance (AMR).[53]

OM-85 offers a fundamentally different paradigm.

• Mechanism Contrast: Prophylactic antibiotics function by directly killing or inhibiting the growth of susceptible bacteria.[53] In contrast, OM-85 does not have direct antimicrobial activity. Instead, it works by modulating and strengthening the host's own immune defenses, priming the body to mount a more effective and rapid response to a wide range of invading pathogens.[4]
• Efficacy and Safety Contrast: A key demonstrated outcome of OM-85 therapy is a significant reduction in the subsequent need for therapeutic courses of antibiotics.[5] By strengthening the host's immunity, it prevents infections from taking hold or reduces their severity, thereby obviating the need for antibiotic treatment. This makes OM-85 a powerful antibiotic-sparing strategy. By avoiding the direct selective pressure on bacteria, its use does not contribute to the development of AMR. This represents a profound strategic advantage and aligns perfectly with global public health initiatives aimed at antimicrobial stewardship.

While OM-85 is not a replacement for antibiotics in the treatment of an established acute bacterial infection, its role in prevention offers a way to break the cycle of recurrent infection and repeated antibiotic exposure.

Differentiation from Traditional Vaccines

Traditional vaccines, such as those for influenza or Streptococcus pneumoniae, are a cornerstone of infectious disease prevention. However, OM-85 occupies a distinct and complementary niche.

• Mechanism Contrast: Conventional vaccines typically work by inducing a highly specific and long-lasting adaptive immune memory against one or a few key antigens from a single pathogen.[55] OM-85, on the other hand, induces a non-specific, broad-spectrum potentiation of the immune system. It creates a state of heightened immune readiness that is not limited to the eight bacterial species in its composition but extends to a wide array of pathogens, including viruses for which specific vaccines may not exist (such as RSV).[17]
• Application Contrast: OM-85 and vaccines are not mutually exclusive; rather, they are complementary and can be used together to provide more comprehensive protection. Clinical studies have demonstrated that the co-administration of OM-85 with the seasonal influenza vaccine is safe and may result in a more pronounced reduction in the overall burden of RTIs than either intervention alone. Importantly, OM-85 does not impair the patient's ability to mount a specific and protective antibody response to the vaccine antigens.[45]

OM-85 thus fills a critical gap left by specific vaccines. While vaccines are indispensable for preventing severe disease caused by specific, high-threat pathogens, OM-85 offers a strategy to reduce the overall morbidity associated with the vast and varied collection of other viruses and bacteria that cause common, recurrent respiratory illnesses.

Future Perspectives and Unmet Needs

The future trajectory of OM-85 will be defined by its ability to navigate the current regulatory landscape and capitalize on emerging scientific insights.

• Strategic Imperative: The most critical near-term objective for the manufacturer is the successful execution and completion of the ongoing U.S. clinical trials, particularly the studies on pediatric wheezing. A positive outcome in these rigorously designed trials would not only unlock the substantial U.S. market but would also generate the high-quality, contemporary evidence needed to satisfy the EMA's 2026 data requirement, thereby securing the product's long-term future in its core European market.
• Potential for Label Expansion: The promising clinical data in atopic dermatitis and allergic asthma represent significant opportunities for label expansion.[23] A successful development program in this area could position OM-85 as a foundational immunomodulatory therapy for altering the atopic march in young children, addressing a major unmet need in pediatric allergy.
• The Antiviral Opportunity: The discovery of OM-85's novel, host-directed antiviral mechanism via downregulation of the ACE2 receptor is a transformative finding.[9] This opens a new and highly valuable strategic avenue for the drug's potential use in pandemic preparedness. Further research to confirm this effect in humans and to explore its activity against other emerging respiratory viruses could elevate OM-85 from a niche prophylactic to a tool of significant public health importance.
• Challenges: The primary challenge remains overcoming the skepticism of key regulatory agencies, which is rooted in the heterogeneity of the historical clinical data. This can only be achieved by generating new, unambiguous data from large, well-controlled, and prospectively defined clinical trials. The company must successfully navigate the high evidentiary bar of the FDA and meet the EMA's deadline to ensure the long-term viability and global success of this unique immunomodulatory agent.

Conclusion

OM-85 (Broncho-Vaxom®) is a well-established immunomodulatory agent with a unique mechanism of action that leverages the gut-lung axis to provide broad, non-specific protection against respiratory pathogens. Its composition, a standardized lysate of eight common respiratory bacteria, stimulates both innate and adaptive immunity, resulting in a state of heightened immune readiness at the respiratory mucosa, primarily mediated by an increase in secretory IgA.

The clinical evidence, supported by decades of use and numerous meta-analyses, confirms its efficacy in reducing the frequency of recurrent respiratory tract infections and decreasing the associated need for antibiotics, particularly in at-risk pediatric populations. Its safety profile is excellent, with adverse events being rare, mild, and comparable to placebo.

Despite its long history and widespread use in 64 countries, OM-85 is at a pivotal moment in its lifecycle. It faces significant regulatory challenges from the EMA and the FDA, which demand contemporary, high-quality evidence to support its legacy claims. The ongoing clinical trials in the United States, focused on the prevention of pediatric wheezing, are therefore of paramount strategic importance. The outcomes of these trials will not only determine its access to the U.S. market but will also profoundly influence its regulatory standing in Europe and across the globe.

Simultaneously, emerging research into its novel, host-directed antiviral mechanisms has opened up exciting new therapeutic possibilities, particularly in the context of pandemic preparedness. By successfully generating the required high-quality clinical data and further elucidating its multifaceted mechanism of action, OM-85 has the potential to transition from a legacy product to a validated, first-in-class immunomodulator for the prevention of a wide spectrum of respiratory diseases.

Works cited

1. OM85: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 20, 2025, https://go.drugbank.com/drugs/DB16533
2. A critical analysis of the effect of OM-85 for the prevention of recurrent respiratory tract infections or wheezing/asthma from systematic reviews with meta-analysis - PubMed, accessed August 20, 2025, https://pubmed.ncbi.nlm.nih.gov/39016384/
3. OM-85 - Wikipedia, accessed August 20, 2025, https://en.wikipedia.org/wiki/OM-85
4. (PDF) Immunomodulation Therapy – Clinical Relevance of Bacterial ..., accessed August 20, 2025, https://www.researchgate.net/publication/338873017_Immunomodulation_Therapy_-_Clinical_Relevance_of_Bacterial_Lysates_OM-85
5. Use of the Bacterial Lysate OM-85 in the Paediatric Population in ..., accessed August 20, 2025, https://www.mdpi.com/1660-4601/18/13/6871
6. Effect of OM-85 on Respiratory Tract Infections and Adenoid Tissue in Children With Adenoid Hypertrophy | ClinicalTrials.gov, accessed August 20, 2025, https://clinicaltrials.gov/study/NCT03243565
7. A critical analysis of the effect of OM-85 for the prevention of recurrent respiratory tract infections or wheezing/asthma from - IU Indianapolis ScholarWorks, accessed August 20, 2025, https://scholarworks.indianapolis.iu.edu/bitstreams/d946d58b-7d14-4511-802c-e380924ab9e0/download
8. OM-85 BV for primary prevention of recurrent airway infections: a pilot randomized, double-blind, placebo-controlled study - SciELO, accessed August 20, 2025, https://www.scielo.br/j/eins/a/DjzKyPFccc7RDV3W8wXFchf/
9. The OM-85 bacterial lysate: a new tool against SARS-CoV-2? - PMC - PubMed Central, accessed August 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9926922/
10. Broncho-Vaxom® (OM-85 BV) soluble components stimulate sinonasal innate immunity, accessed August 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6438742/
11. OM-85 in the prevention of respiratory infections: State-of-the-art and future perspectives in clinical practice - ResearchGate, accessed August 20, 2025, https://www.researchgate.net/publication/352693499_OM-85_in_the_prevention_of_respiratory_infections_State-of-the-art_and_future_perspectives_in_clinical_practice
12. Prevention of paediatric respiratory tract infections: emphasis on the role of OM-85, accessed August 20, 2025, https://publications.ersnet.org/content/errev/14/95/74
13. Bacterial extract (OM-85) with human-equivalent doses does not inhibit the development of asthma in a murine model | Allergologia et Immunopathologia - Elsevier, accessed August 20, 2025, https://www.elsevier.es/en-revista-allergologia-et-immunopathologia-105-articulo-bacterial-extract-om-85-with-human-equivalent-S0301054616300726
14. Oral Bacterial Lysate OM-85: Advances in Pharmacology and Therapeutics - Dove Medical Press, accessed August 20, 2025, https://www.dovepress.com/article/download/96086
15. Efficacy and safety of OM-85 in pediatric recurrent respiratory tract infections which could have a possible protective effect in COVID-19 pandemic: A meta-analysis - ResearchGate, accessed August 20, 2025, https://www.researchgate.net/publication/348276885_Efficacy_and_safety_of_OM-85_in_pediatric_recurrent_respiratory_tract_infections_which_could_have_a_possible_protective_effect_in_COVID-19_pandemic_A_meta-analysis
16. Use of OM-85 BV in children suffering from recurrent respiratory tract infections and subnormal IgG subclass levels | Allergologia et Immunopathologia - Elsevier, accessed August 20, 2025, https://www.elsevier.es/en-revista-allergologia-et-immunopathologia-105-articulo-use-om-85-bv-in-children-13042838
17. Airway Administration of Bacterial Lysate OM-85 Protects ... - Frontiers, accessed August 20, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.867022/full
18. Efficacy and safety of OM‐85 in paediatric recurrent respiratory tract infections which could have a possible protective effect on COVID‐19 pandemic: A meta‐analysis - PMC - PubMed Central, accessed August 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7883224/
19. Brief research report: OM-85 reduces SARS-COV-2 viral RNA expression in nasopharyngeal cells from COVID-19 patients - Frontiers, accessed August 20, 2025, https://www.frontiersin.org/journals/virology/articles/10.3389/fviro.2023.1111619/full
20. Respiratory Tract Bacterial Extracts Could Prevent COVID-19, Study Finds, accessed August 20, 2025, https://healthsciences.arizona.edu/news/releases/respiratory-tract-bacterial-extracts-could-prevent-covid-19-study-finds
21. Full article: Expert consensus on the role of OM-85 in the management of recurrent respiratory infections: A Delphi study, accessed August 20, 2025, https://www.tandfonline.com/doi/full/10.1080/21645515.2022.2106720
22. Bacterial lysate medicines for respiratory conditions to be used only ..., accessed August 20, 2025, https://www.ema.europa.eu/en/news/bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections
23. Oral bacterial lysate OM-85 prevents Respiratory Tract Infections in ..., accessed August 20, 2025, https://www.dovepress.com/oral-bacterial-lysate-om-85-prevents-respiratory-tract-infections-in-a-peer-reviewed-fulltext-article-JAA
24. [PDF] OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review | Semantic Scholar, accessed August 20, 2025, https://www.semanticscholar.org/paper/OM-85-BV%2C-an-immunostimulant-in-pediatric-recurrent-Schaad/c115732cd88eee01e9d368a55a991e0412332912
25. OM 85 to Prevent Respiratory Infections in Older At Risk Patients - ClinicalTrials.gov, accessed August 20, 2025, https://clinicaltrials.gov/study/NCT06655272
26. OM85 Completed Phase 1 Trials for Asthma, Allergic Treatment | DrugBank Online, accessed August 20, 2025, https://go.drugbank.com/drugs/DB16533/clinical_trials?conditions=DBCOND0047182&phase=1&purpose=treatment&status=completed
27. Asthma Atopic Recruiting Phase 1 Trials for OM85 (DB16533) | DrugBank Online, accessed August 20, 2025, https://go.drugbank.com/indications/DBCOND0116374/clinical_trials/DB16533?phase=1&status=recruiting
28. OM85 Completed Phase 3 Trials for Atopic Dermatitis Prevention | DrugBank Online, accessed August 20, 2025, https://go.drugbank.com/drugs/DB16533/clinical_trials?conditions=DBCOND0028414&phase=3&purpose=prevention&status=completed
29. Study Details | Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD, accessed August 20, 2025, https://clinicaltrials.gov/study/NCT05222516
30. Effect of OM-85 BV on Wheezing Related Morbidity in Children With Recurrent Wheezing, accessed August 20, 2025, https://clinicaltrials.gov/study/NCT00733226
31. PRESS RELEASE - OM Pharma, accessed August 20, 2025, https://www.ompharma.com/system/files/2022-12/Press%20Release_OM%20Pharma%20successfully%20submitted%20an%20IND%20application%20to%20the%20FDA.pdf
32. OM Pharma successfully submitted an IND application to the FDA ..., accessed August 20, 2025, https://www.ompharma.com/media/news/0b8600bc-b5a3-4490-b603-58342becaadb
33. Daily OM-85 in Young Children With Recurrent Wheezing - UCSF Clinical Trials, accessed August 20, 2025, https://clinicaltrials.ucsf.edu/trial/NCT05857930
34. Effects of an Immunostimulating Agent on Acute Exacerbations and Hospitalizations in Patients with Chronic Obstructive Pulmonary Disease | American Journal of Respiratory and Critical Care Medicine, accessed August 20, 2025, https://www.atsjournals.org/doi/10.1164/ajrccm.156.6.9612096
35. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review - University of York, accessed August 20, 2025, http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?AccessionNumber=12010001801
36. Economic Analysis of the Immunostimulant OM-85 for the Prevention of Paediatric Recurrent Upper Respiratory Tract Infections | Global and Regional Health Technology Assessment - AboutScience, accessed August 20, 2025, https://journals.aboutscience.eu/index.php/grhta/article/view/338
37. OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis - PMC, accessed August 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9724379/
38. OM-85 (Broncho-Vaxom) - Bronchiectasis News Today, accessed August 20, 2025, https://bronchiectasisnewstoday.com/bronchiectasis-experimental-treatments/om-85-broncho-vaxom/
39. Broncho Vaxom is a medication that enhances respiratory immunity - Vinmec, accessed August 20, 2025, https://www.vinmec.com/eng/blog/broncho-vaxom-is-a-respiratory-immune-booster-en
40. An Open Multicenter Study Using Broncho-Vaxom® as an Adjunt Therapy for the Treatment a Prevention of Respiratory Community Aquired Infections in Children., accessed August 20, 2025, http://oldfiles.bjorl.org/conteudo/acervo/acervo_english.asp?id=2532
41. Broncho-Vaxom® - MedEx, accessed August 20, 2025, https://medex.com.bd/attachments/ubVjcizaVtrd2lEnQ9TeExTLbCm0DM/lyophilized-bacterial-lysates-prescribing-information
42. Broncho-Vaxom | 7 mg | Capsule | ZAS Corporation - MedEx, accessed August 20, 2025, https://medex.com.bd/index.php/brands/35658/broncho-vaxom-7-mg-capsule
43. Broncho Vaxom: Uses, Price, Dosage, Side Effects, Substitute, Buy Online - myUpchar, accessed August 20, 2025, https://www.myupchar.com/en/medicine/broncho-vaxom-p37105820
44. (PDF) Impact of OM-85 Given during Two Consecutive Years to Children with a History of Recurrent Respiratory Tract Infections: A Retrospective Study - ResearchGate, accessed August 20, 2025, https://www.researchgate.net/publication/332625248_Impact_of_OM-85_Given_during_Two_Consecutive_Years_to_Children_with_a_History_of_Recurrent_Respiratory_Tract_Infections_A_Retrospective_Study
45. Impact of OM-85 Given during Two Consecutive Years to Children with a History of Recurrent Respiratory Tract Infections: A Retrospective Study - MDPI, accessed August 20, 2025, https://www.mdpi.com/1660-4601/16/6/1065
46. Expert consensus on the role of OM-85 in the management of recurrent respiratory infections: A Delphi study - ResearchGate, accessed August 20, 2025, https://www.researchgate.net/publication/362810525_Expert_consensus_on_the_role_of_OM-85_in_the_management_of_recurrent_respiratory_infections_A_Delphi_study
47. Bacterial lysates-containing medicinal products indicated for respiratory conditions - referral, accessed August 20, 2025, https://www.ema.europa.eu/en/medicines/human/referrals/bacterial-lysates-containing-medicinal-products-indicated-respiratory-conditions
48. Double-Blind, Placebo-Controlled, Randomised Clinical Study of Broncho-Vaxom® in Children Suffering from Recurrent Upper Respiratory Tract Infections - EU Clinical Trials Register, accessed August 20, 2025, https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002980-17/results
49. OM Pharma and Medinfar enter into exclusive agreement to promote Broncho-Vaxom® in Portugal, accessed August 20, 2025, https://www.ompharma.com/system/files/2022-09/OM%20Pharma%20and%20Medinfar%20enter%20into%20exclusive%20agreement%20to%20promote%20Broncho-Vaxom%20in%20Portugal.pdf
50. The OM-85 bacterial lysate inhibits SARS-CoV-2 infection of epithelial cells by downregulating SARS-CoV-2 receptor expression - PubMed Central, accessed August 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8660661/
51. OM85: could bacteria in a capsule protect us from coronavirus and other respiratory infections? - Faculty of Medicine - The University of Queensland, accessed August 20, 2025, https://medicine.uq.edu.au/article/2020/06/om85-could-bacteria-capsule-protect-us-coronavirus-and-other-respiratory-infections
52. Human Drugs View - FDA Verification Portal - Food and Drug Administration, accessed August 20, 2025, https://verification.fda.gov.ph/drug_productsview.php?showdetail=®istration_number=BR-1440
53. Study protocol for a randomised controlled trial evaluating the clinical effect of antibiotic prophylaxis in children with recurrent respiratory tract infections - BMJ Open, accessed August 20, 2025, https://bmjopen.bmj.com/content/11/7/e044505
54. Bacterial lysate (BL) OM-85 reduces number and severity of respiratory tract infections (RTIs) in adults with allergic asthma: a RWE retrospective study - ERS Publications, accessed August 20, 2025, https://publications.ersnet.org/content/erj/64/suppl68/pa3573
55. Expert consensus on the role of OM-85 in the management of recurrent respiratory infections: A Delphi study - PMC, accessed August 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9746428/